Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
JW (Cayman) Therapeutics Co. Ltd. ( (HK:2126) ) has shared an update.
JW (Cayman) Therapeutics Co. Ltd. has announced an extraordinary general meeting scheduled for June 3, 2025, to approve a License Agreement and related transactions. This meeting is crucial for the company’s strategic operations, potentially impacting its market positioning and stakeholder interests.
More about JW (Cayman) Therapeutics Co. Ltd.
JW (Cayman) Therapeutics Co. Ltd. is a biotechnology company incorporated in the Cayman Islands, focusing on the development and commercialization of cell-based immunotherapies for cancer treatment.
Average Trading Volume: 2,029,637
Technical Sentiment Signal: Sell
Current Market Cap: HK$699.2M
See more data about 2126 stock on TipRanks’ Stock Analysis page.